Trials / Completed
CompletedNCT02731911
Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
Phase 4, Open-label, Non-randomized, Prospective Study of OZURDEX® in the Treatment of Diabetic Macular Oedema - The AUSSIEDEX Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 202 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective study will assess Ozurdex in the treatment of Diabetic Macular Oedema in clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dexamethasone intravitreal implant | Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice. |
Timeline
- Start date
- 2016-04-29
- Primary completion
- 2018-10-22
- Completion
- 2018-10-22
- First posted
- 2016-04-08
- Last updated
- 2019-01-23
Locations
23 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT02731911. Inclusion in this directory is not an endorsement.